Bli medlem
Bli medlem

Du är här


Orexo: Number of shares and votes in Orexo

Uppsala, Sweden - May 30, 2014 - The number of shares and votes in
Orexo AB has changed as a result of the exercise of warrants in
connection with the company's incentive programs.

Today, the last trading day of the month, there are in total
32,944,983 shares and votes in the company.

For further information, please contact:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)18-780 88 00, E-mail:

About Orexo
Orexo is a specialty pharmaceutical company with commercial operations
in the United States and R&D in Sweden developing improved treatments
using proprietary drug delivery technology. The company is
commercializing its proprietary product, Zubsolv® (buprenorphine and
naloxone), in the United States for maintenance treatment of opioid
dependence. Zubsolv is a novel sublingual formulation of
buprenorphine and naloxone using Orexo's extensive knowledge in
sublingual technologies. Orexo has a portfolio of two approved and
revenue generating products currently marketed under license in the
US, EU and Japan. Orexo's development expertise is within the area of
reformulation technologies, and especially sublingual formulations.
Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX.
The largest shareholders are Novo A/S and HealthCap.

For information about Orexo please visit

Orexo AB (publ) discloses the information provided herein pursuant to
the Financial Instruments Trading Act and/or the Securities Markets
Act. The information was submitted for publication at 4:30 pm CET on
May 30, 2014.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.